OverviewSuggest Edit

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The Company’s pipeline focuses in three strategic therapeutic areas (STArs): genetic medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; cardio-metabolic disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases.

TypePublic
Founded2002
HQCambridge, US
Websitealnylam.com
Employee Ratings4
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)1,323(+25%)
Job Openings50
Revenue (FY, 2019)$219.8 M(+194%)
Share Price (Nov 2020)$124.7
Cybersecurity ratingAMore

Key People/Management at Alnylam Pharmaceuticals

Yvonne Greenstreet

Yvonne Greenstreet

COO
Pushkal Garg

Pushkal Garg

Chief Medical Officer
Al Boyle

Al Boyle

SVP, Technical Operations
Laurie Keating

Laurie Keating

EVP, Chief Legal Officer and Secretary
John Maraganore

John Maraganore

CEO
Jeff Poulton

Jeff Poulton

Chief Financial Officer
Show more

Alnylam Pharmaceuticals Office Locations

Alnylam Pharmaceuticals has offices in Cambridge, Paris, Milano, Amsterdam and in 3 other locations
Cambridge, US (HQ)
300 Third St
Paris, FR
100 Avenue de Suffren
Milano, IT
Via Pola, 11
Amsterdam, NL
Strawinskylaan 3051
Stockholm, SE
Olof Palmes gata 29
Zug, CH
Grafenauweg 4
Show all (7)

Alnylam Pharmaceuticals Financials and Metrics

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals's revenue was reported to be $219.75 m in FY, 2019
USD

Revenue (Q3, 2020)

99.2m

Market capitalization (20-Nov-2020)

14.4b

Closing stock price (20-Nov-2020)

124.7

Cash (30-Sept-2020)

496.7m

EV

14.2b
Alnylam Pharmaceuticals's current market capitalization is $14.4 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

100.0m74.9m219.8m

Cost of goods sold

1.8m25.1m

Gross profit

73.1m194.7m

Gross profit Margin, %

98%89%
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

26.6m27.7m20.9m29.9m2.1m33.3m44.7m46.1m99.5m77.5m99.2m

Cost of goods sold

137.0k3.3m4.3m13.3m

Gross profit

1.9m29.9m40.4m86.2m

Gross profit Margin, %

93%90%90%87%
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

74.6m70.2m51.4m53.2m75.2m180.9m193.6m645.4m420.1m547.2m

Accounts Receivable

3.5m1.5m104.0k4.2m39.9m8.3m17.9m34.0m18.8m43.0m

Prepaid Expenses

4.2m2.5m3.9m9.7m16.6m40.1m73.7m80.3m

Inventories

21.7m24.1m56.3m
USDQ2, 2010

Financial Leverage

2.7 x
Show all financial metrics

Alnylam Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Alnylam Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Alnylam Pharmaceuticals Online and Social Media Presence

Embed Graph

Alnylam Pharmaceuticals Company Culture

  • Overall Culture

    B

    76/100

  • CEO Rating

    A+

    95/100

  • Compensation

    A+

    97/100

Learn more on Comparably

Alnylam Pharmaceuticals Blogs

New Results for ALN-AGT at AHA Scientific Sessions 2020

Positive interim results from the ongoing Phase 1 study of ALN-AGT, an investigational RNAi therapeutic for the treatment of hypertension, were presented during the American Heart Association (AHA) Scientific Sessions 2020, taking place virtually from November 13 – 17, 2020. Read the press release V…

New Results for GIVLAARI® (givosiran) at the Thrombosis & Hemostasis Summit of North America 2020 Virtual Conference

During the Thrombosis & Hemostasis Summit of North America 2020 Virtual Conference, we presented new data from a post-hoc analysis of the ENVISION Phase 3 study of GIVLAARI® (givosiran), evaluating hemin use in patients with acute hepatic porphyria. We also presented encore data evaluating healt…

New Results for GIVLAARI® (givosiran) at the American College of Gastroenterology 2020 Virtual Annual Scientific Meeting

New data from a post-hoc analysis of the ENVISION Phase 3 study of GIVLAARI® (givosiran) were presented during the American College of Gastroenterology 2020 Virtual Annual Scientific Meeting, evaluating outcomes in patients with acute hepatic porphyria with or without prior hemin prophylaxis. Findin…

ILLUMINATE-B Phase 3 Results for Lumasiran Presented at ASN

Positive results from the six-month primary analysis of the ongoing ILLUMINATE-B Phase 3 open-label pediatric study of lumasiran, an investigational RNAi therapeutic in development for the treatment of adults and children with Primary Hyperoxaluria Type 1 (PH1), were presented at the American Societ…

RNAi Therapeutics Platform Progress at OTS 2020 Annual Meeting

We presented progress on our RNAi therapeutics platform efforts at the Oligonucleotide Therapeutics Society (OTS) 2020 Annual Meeting. Akinc et al. – “ALN-COV: An Investigational RNAi Therapeutic for COVID-19” Brown et al. – “Evidence for an Intracellular Depot that Contributes to the Extended Durat…

RNAi Roundtable: Givosiran, for the Treatment of Acute Hepatic Porphyria

On September 14, 2020, we hosted an online RNAi Roundtable to review progress with givosiran, an RNAi therapeutic for the treatment of acute hepatic porphyria. Access the replay View the presentation Read the transcript Akin Akinc, Ph.D. Vice President & General Manager, Givosiran Gail Hartigan.…
Show more

Alnylam Pharmaceuticals Frequently Asked Questions

  • When was Alnylam Pharmaceuticals founded?

    Alnylam Pharmaceuticals was founded in 2002.

  • Who are Alnylam Pharmaceuticals key executives?

    Alnylam Pharmaceuticals's key executives are Yvonne Greenstreet, Pushkal Garg and Al Boyle.

  • How many employees does Alnylam Pharmaceuticals have?

    Alnylam Pharmaceuticals has 1,323 employees.

  • What is Alnylam Pharmaceuticals revenue?

    Latest Alnylam Pharmaceuticals annual revenue is $219.8 m.

  • What is Alnylam Pharmaceuticals revenue per employee?

    Latest Alnylam Pharmaceuticals revenue per employee is $166.1 k.

  • Who are Alnylam Pharmaceuticals competitors?

    Competitors of Alnylam Pharmaceuticals include Celyad, Sorrento Therapeutics and Moderna.

  • Where is Alnylam Pharmaceuticals headquarters?

    Alnylam Pharmaceuticals headquarters is located at 300 Third St, Cambridge.

  • Where are Alnylam Pharmaceuticals offices?

    Alnylam Pharmaceuticals has offices in Cambridge, Paris, Milano, Amsterdam and in 3 other locations.

  • How many offices does Alnylam Pharmaceuticals have?

    Alnylam Pharmaceuticals has 7 offices.